Emiltatug Biosimilar – Anti-V-set domain-containing T-cell activation inhibitor 1 mAb – Research Grade

Description of Emiltatug Biosimilar - Anti-V-set domain-containing T-cell activation inhibitor 1 mAb - Research Grade

Introduction

Emiltatug Biosimilar is a therapeutic antibody that targets the V-set domain-containing T-cell activation inhibitor 1 (VISTA) protein. This monoclonal antibody (mAb) is a research grade product that has shown promising results in pre-clinical studies for the treatment of various diseases. In this article, we will discuss the structure, activity, and potential applications of Emiltatug Biosimilar.

Structure of Emiltatug Biosimilar

Emiltatug Biosimilar is a recombinant humanized IgG1 monoclonal antibody that is produced in CHO cells. It has a molecular weight of approximately 150 kDa and consists of two heavy chains and two light chains. The heavy chains contain four constant domains (CH1, CH2, CH3, and CH4) and one variable domain (VH), while the light chains contain two constant domains (CL and CH1) and one variable domain (VL). The variable domains of Emiltatug Biosimilar are responsible for binding to the VISTA protein.

Activity of Emiltatug Biosimilar

VISTA is a cell surface protein that is expressed on various immune cells, including T cells, B cells, and myeloid cells. It is known to act as a negative regulator of immune response, and its overexpression has been linked to the progression of various diseases, including cancer and autoimmune disorders. Emiltatug Biosimilar binds to VISTA and blocks its inhibitory activity, thereby promoting immune response against these diseases.

In pre-clinical studies, Emiltatug Biosimilar has shown potent anti-tumor activity by enhancing the function of T cells and natural killer cells. It has also been shown to inhibit the growth of certain autoimmune cells, making it a potential treatment option for autoimmune diseases.

Potential Applications of Emiltatug Biosimilar

Emiltatug Biosimilar has shown promising results in pre-clinical studies for the treatment of various diseases, including cancer and autoimmune disorders. Its ability to block VISTA’s inhibitory activity makes it a potential therapeutic option for cancers that overexpress VISTA, such as lung cancer, breast cancer, and melanoma. It can also be used in combination with other cancer treatments, such as chemotherapy and immunotherapy, to enhance their efficacy.

In addition to cancer, Emiltatug Biosimilar has also shown potential in the treatment of autoimmune diseases, such as rheumatoid arthritis and multiple sclerosis. By inhibiting the function of VISTA, it can suppress the overactive immune response that is responsible for these diseases.

Conclusion

Emiltatug Biosimilar is a promising therapeutic antibody that targets the VISTA protein. Its structure, consisting of humanized IgG1, makes it suitable for use in humans. Its activity in blocking VISTA’s inhibitory function has shown potential in the treatment of various diseases, including cancer and autoimmune disorders. As a research grade product, Emiltatug Biosimilar is currently undergoing further studies and has the potential to be developed into a clinically approved therapeutic option in the future.